Farxiga Cuts A1c in Pediatric Diabetes; Late-Stage CAH Win; At-Home Menopause Test

(MedPage Today) -- Dapagliflozin (Farxiga) lowered HbA1c by 1.03 percentage points more than placebo in children and adolescents with type 2 diabetes, while saxagliptin (Onglyza) showed no significant reduction versus placebo, the phase III T2NOW...
Source: MedPage Today Endocrinology - Category: Endocrinology Source Type: news